Revive Therapeutics Ltd.

CNSX: RVV


Canadian symbol: RVV.CN
US symbol: RVVTF

Currency in CAD

Valuation Measures

Market Cap (intraday) 549.18M
Enterprise Value 340.87M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)8.11
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-15.80

Trading Information

Stock Price History

Beta (5Y Monthly) -0.93
52-Week Change 3233.33%
S&P500 52-Week Change 35.66%
52 Week High 30.3900
52 Week Low 30.0250
50-Day Moving Average 30.2547
200-Day Moving Average 30.1306

Share Statistics

Avg Vol (3 month) 32.48M
Avg Vol (10 day) 37.9M
Shares Outstanding 5163.95M
Float 156.68M
% Held by Insiders 18.51%
% Held by Institutions 10.00%
Shares Short (Jun. 14, 2020) 42.85M
Short Ratio (Jun. 14, 2020) 41.71
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 41.74%
Shares Short (prior month May 14, 2020) 4527.01k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun. 29, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-37.73%
Return on Equity (ttm)-75.47%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -2.59M
Net Income Avi to Common (ttm)-2.8M
Diluted EPS (ttm)-0.0380
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)712.55k
Total Cash Per Share (mrq)0
Total Debt (mrq)591.17k
Total Debt/Equity (mrq)9.80
Current Ratio (mrq)0.92
Book Value Per Share (mrq)0.04

Cash Flow Statement

Operating Cash Flow (ttm)-1.75M
Levered Free Cash Flow (ttm)-824.41k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
RVV.CN
Revive Therapeutics
4 weeks ago
RVV.CN
Revive Therapeutics
1 month ago
RVV.CN
Revive Therapeutics
1 month ago
RVV.CN
Revive Therapeutics
2 months ago
RVV.CN
Revive Therapeutics
2 months ago
RVV.CN
Revive Therapeutics
2 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
4 months ago
RVV.CN
Revive Therapeutics
5 months ago
RVV.CN
Revive Therapeutics
6 months ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
8.51%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Revive Therapeutics Ltd.


Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

TORONTO, June 30, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has submitted today its Investigational New Drug (“IND”) application to the U.S. Food and Drug ... Read More...
Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an expansion to the sponsored research partnership agreement (“SRPA”) entered with the University ... Read More...
Revive Therapeutics Provides Update on Discussions with Health Canada in Pre-CTA Meeting

Revive Therapeutics Provides Update on Discussions with Health Canada in Pre-CTA Meeting

TORONTO, June 09, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company met with Health Canada in a Pre-Clinical Trial Application (“Pre-CTA”) meeting to... Read More...
Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

TORONTO, June 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has filed its Clinical Trial Application (“Pre-CTA”) with Health Canada and provides an up... Read More...
Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

TORONTO, May 13, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its pharmaceutical programs for Bucillamine in the treatment of the coronaviru... Read More...
Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

TORONTO, April 29, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide further insight on its plans for its psilocybin-based pharmaceutical program.  The Company will in... Read More...
Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

TORONTO, April 23, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has received positive feedback from the U.S. Food and Drug Administration (“FDA”) in response to... Read More...
Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals

TORONTO, April 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has entered into a sponsored research partnership agreement (“SRPA”) with the University of Wisc... Read More...
Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

TORONTO, April 17, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has engaged Complete Phytochemical Solutions, LLC., an internationally-recognized company specia... Read More...
Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

NewsThe Daily BeastBarr Pressed Australia for Help on Mueller Review as DOJ Worked to Free Its HostagesIn a series of conversations last September, senior Department of Justice officials worked with representatives of the Australian government to hammer out an arrangement to win the release of a pair of Australian bloggers imprisoned in T... Read More...
Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

TORONTO, April 08, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, is pleased to announce that the Company has retained Novotech, the largest biotech clinical research organization (“CRO”) sp... Read More...
Investor Announcement

Investor Announcement

TORONTO, April 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany. The Company, along with the Federal Financial Supervisory Authority of Germany (“BaFin”) suggests shareholders fully understand these material... Read More...
Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

TORONTO, March 30, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, is pleased to provide a corporate update on its plans for the Company’s coronavirus disease (“COVID-19”) and infectious dise... Read More...
Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

TORONTO, March 25, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC, with proven clinical experience in infectious diseases... Read More...
Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

TORONTO, March 24, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as a Scientific Advisor to guide on the Company’s current and future clinical programs including its research and development s... Read More...
Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

TORONTO, March 20, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19). The Company has applied for a pr... Read More...
Revive Therapeutics Announces Closing of Brokered Private Placement

Revive Therapeutics Announces Closing of Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, March 18, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a cannabis and psychedelic life sciences company, is pleased to announce that further to its... Read More...
Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

TORONTO, March 05, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products, is pleased to announce that, further to its press release of February 12, 2020, the Company has completed its acquisition o... Read More...
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, Feb. 18, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical development plan for Cannabidiol (“CBD”) in the treatment of Autoimmune Hepati... Read More...
Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

TORONTO, Feb. 12, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the “LOI”) with Psilocin Pharma Corp. (“Psilocin”), an arm’s length party incorporated pursuant to the laws of the Province of Ontario. Pursuant to the terms of the LOI... Read More...
Revive Therapeutics Announces Brokered Private Placement of up to $2 million

Revive Therapeutics Announces Brokered Private Placement of up to $2 million

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, Feb. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory dis... Read More...
Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing

Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing

TORONTO, Feb. 10, 2020 -- Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has entered into a supply and collaboration agreement (the “Agreement”) with Red Light Holland Financing Inc. (“Red Light”), an arm’s l... Read More...
Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units

Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units

TORONTO, Feb. 05, 2020 -- Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the “Debenture Units”) to arm’s length parties for aggregate gross proceeds of ... Read More...
Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

TORONTO, Jan. 20, 2020 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s announcement on January 6, 2020 regarding its clinical development plan on live... Read More...
Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases

Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases

TORONTO, Jan. 06, 2020 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical development plan for Autoimmune liver diseases, which includes Cannabidiol in t... Read More...
Revive Therapeutics Provides Update on its Cannabis-based Pharmaceutical Initiatives

Revive Therapeutics Provides Update on its Cannabis-based Pharmaceutical Initiatives

TORONTO, Dec. 19, 2019 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE:RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel th... Read More...
Revive Therapeutics Announces New Leadership Appointment and Board Change

Revive Therapeutics Announces New Leadership Appointment and Board Change

TORONTO, Dec. 18, 2019 -- Revive Therapeutics Ltd. (“Revive" and the “Company") (CSE: RW), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that all the resolutions put forward by the Company at its annual general meeting of shareholder... Read More...
Revive Therapeutics Announces Results for the Three Months Ended September 30, 2019

Revive Therapeutics Announces Results for the Three Months Ended September 30, 2019

TORONTO, Nov. 27, 2019 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, today announced its results for the three months ended September 30, 2019.  The unaudited condensed interim... Read More...
Revive Therapeutics Announces Approval of CSE Listing and Delisting from TSX-V

Revive Therapeutics Announces Approval of CSE Listing and Delisting from TSX-V

TORONTO, July 19, 2019 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that it has received final approval to list its common shares on the Canadian... Read More...
Revive Therapeutics Announces Cannabis Product Derivative Manufacturing and Development Facility

Revive Therapeutics Announces Cannabis Product Derivative Manufacturing and Development Facility

TORONTO, June 20, 2019 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that the Company is to establish a cannabis product derivative manufacturing ... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
Michael Frank
Chairman of the Board, Chief Executive Officer
--Chairman of the Board, Chief Executive Officer2019
Carmelo Marrelli
Chief Financial Officer, Secretary
--Chief Financial Officer, Secretary2015
Robbie Grossman
Director
--Director2015
Scott Johnson
Director
36Director--
Anton Konovalov
Director
26Director--
Andrew Lindzon
Director
--Director2019
Reiza Rayman
Director
53Director--
Christian Scovenna
Director
--Director2019


Share this page